Academic Journal
Προβολή σε EDS

Evidence- and opinion-based consensus from Delphi round 1 of the Asian aplastic anemia recommendation development.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Evidence- and opinion-based consensus from Delphi round 1 of the Asian aplastic anemia recommendation development.
Συγγραφείς: Jang JH; Department of Hematology (Oncology), Samsung Medical Center, Seoul, South Korea., Kwong YL; The University of Hong Kong, Pok Fu Lam, Hong Kong., Issaragrisil S; Siriraj Hospital, Mahidol University, Salaya, Thailand., Hosokawa K; Department of Hematology, Kanazawa University Hospital, Kanazawa, Japan., Yao M; Department of Internal Medicine, National Taiwan University, Taipei, Taiwan., Chen YC; Division of Hematology/Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan., Mun YC; Department of Hematology, Ewha Womans University College of Medicine, Seoul, South Korea., Zhang FK; Anemia Therapeutic Center, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China., Wong L; Department of Hematology, Hospital Queen Elizabeth, Kota Kinabalu, Malaysia., Nakao S; Department of Hematology, Kanazawa University, Kanazawa, Japan. snakao8205@staff.kanazawa-u.ac.jp.
Πηγή: International journal of hematology [Int J Hematol] 2026 Oct; Vol. 124 (4), pp. 521-537. Date of Electronic Publication: 2026 Jul 22.
Τύπος έκδοσης: Journal Article; Consensus Statement
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: Springer Japan Country of Publication: Japan NLM ID: 9111627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-3774 (Electronic) Linking ISSN: 09255710 NLM ISO Abbreviation: Int J Hematol Subsets: MEDLINE
Imprint Name(s): Publication: 2008- : Tokyo : Springer Japan
Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
Ιατρικοί όροι (MeSH): Anemia, Aplastic*/diagnosis , Anemia, Aplastic*/therapy , Anemia, Aplastic*/etiology , Anemia, Aplastic*/epidemiology , Delphi Technique* , Evidence-Based Medicine*, Humans ; Asia ; Consensus ; Practice Guidelines as Topic
Περίληψη: Background: Implementing international guidelines for aplastic anemia (AA) in Asia remains challenging due to limited access to advanced diagnostic tools, restricted treatment options, and variation in healthcare policies. This highlights a need for region-specific guidance on the diagnosis and management of AA in Asia.
Methods: The Asian Aplastic Anemia Working Group consisted of 10 experts from across Asia (South Korea, Japan, China, Hong Kong, Malaysia, Taiwan, and Thailand) who met virtually twice and developed 16 thematic statements on the diagnosis and management of AA. Using an e-Delphi method, members voted asynchronously on these statements using a 5-point Likert scale. Consensus was predefined as "≥ 80% level of agreement among the Delphi participants."
Results: Sixteen thematic statements and 54 sub-statements were developed. The first three statements addressed AA definition, presentation, and causes; the next four focused on diagnosis and prognosis; and the remaining nine covered management, including clonal evolution, supportive care, and special populations. Fifteen statements reached consensus after the first voting round. However, one statement on the management of severe AA did not achieve consensus in the first round.
Conclusion: This e-Delphi method has, for the first time, generated Asian, expert-derived, consensus recommendations for the diagnosis and management of AA.
(© 2026. The Author(s).)
Competing Interests: Declarations. Conflict of interest: Jun Ho Jang received medical writing support. Yok Lam Kwong received honoraria for lectures from Amgen, Astellas, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Janssen, Merck, Otsuka, Novartis, Roche, and Takeda; and participated in advisory boards for Amgen, Astellas, Bayer, BeiGene, Bristol Myers Squibb, Celgene, Janssen, Merck, Otsuka, Novartis, Roche, and TakedaSupport for attending EBMT meetings 2024 and 2025 was received from Sanofi. Surapol Issaragrisil is the editor of International Journal of Hematology. Kohei Hosokawa received honoraria for lectures from Alexion Pharmaceuticals, Inc.; Chugai Pharmaceutical Co., Ltd.; Novartis Pharma K.K.; Kyowa Kirin Co., Ltd.; and Bristol-Myers Squibb K.K., and served an unpaid leadership role as a board member of the International PNH Interest Group (IPIG). Yeu-Chin Chen received speaker fees from Bayer, Chugai, CSL Behring, Kirin, Sanofi, AstraZeneca, BeiGene, Bristol Myers Squibb, Kirin, Novartis, PharmaEssential, Roche, and Takeda and received grant support by Shire and Sanofi. Lily Wong participated in the Aplastic Anemia Advisory Board. Shinji Nakao received honoraria for lectures from Novartis Pharma K.K., Kyowa Kirin Co., Ltd., Asahi Kasei Co., SymBio Pharmaceuticals Inc., and Alexion Pharmaceuticals, Inc. Ming Yao, Yeung-Chul Mun, and Zhang FK declare that they have no conflict of interest.
References: Br J Haematol. 1989 Dec;73(4):541-5. (PMID: 2611139)
Cancer Genet. 2015 Apr;208(4):115-28. (PMID: 25800665)
Haematologica. 2015 Dec;100(12):1546-52. (PMID: 26315930)
Int J Hematol. 2019 Aug;110(2):187-196. (PMID: 31183813)
Korean J Hematol. 2012 Jun;47(2):126-30. (PMID: 22783359)
Blood. 2018 Apr 26;131(17):1989-1992. (PMID: 29549172)
N Engl J Med. 2007 Nov 29;357(22):2237-47. (PMID: 18046028)
N Engl J Med. 2011 Aug 4;365(5):430-8. (PMID: 21812672)
Ann Intern Med. 2012 Jul 3;157(1):49-58. (PMID: 22751760)
Blood. 2017 Mar 16;129(11):1428-1436. (PMID: 28096088)
Blood. 2005 Dec 1;106(12):3699-709. (PMID: 16051736)
Hematology Am Soc Hematol Educ Program. 2011;2011:76-81. (PMID: 22160015)
Blood. 2007 Sep 1;110(5):1603-6. (PMID: 17463169)
Rinsho Ketsueki. 2018;59(10):1969-1978. (PMID: 30305499)
N Engl J Med. 2022 Jan 6;386(1):11-23. (PMID: 34986284)
J Adv Nurs. 2003 Feb;41(4):376-82. (PMID: 12581103)
Blood. 2006 Feb 15;107(4):1308-14. (PMID: 16179371)
Blood. 2011 Dec 15;118(25):6601-9. (PMID: 21963603)
Hematology Am Soc Hematol Educ Program. 2011;2011:90-5. (PMID: 22160018)
Blood. 1989 Feb;73(2):606-13. (PMID: 2644980)
Blood. 2007 May 15;109(10):4582-5. (PMID: 17272503)
Blood. 2012 Aug 9;120(6):1185-96. (PMID: 22517900)
J Clin Oncol. 2007 Dec 1;25(34):5471-89. (PMID: 17909198)
Clin Transplant. 2018 Feb;32(2):. (PMID: 29297952)
Front Med (Lausanne). 2022 Mar 07;9:805197. (PMID: 35342744)
Br J Haematol. 2009 Oct;147(1):43-70. (PMID: 19673883)
Hematol Oncol Clin North Am. 2018 Aug;32(4):629-642. (PMID: 30047416)
Curr Hematol Malig Rep. 2012 Dec;7(4):300-9. (PMID: 22936422)
Blood. 2014 Oct 23;124(17):2698-704. (PMID: 25139356)
Ann Hematol. 2021 Oct;100(10):2443-2452. (PMID: 34269837)
Blood. 2014 Jul 17;124(3):334-43. (PMID: 24914138)
Haematologica. 2019 Feb;104(2):256-262. (PMID: 30262561)
Blood. 2011 Jun 23;117(25):6876-84. (PMID: 21527527)
Br J Haematol. 2021 Jan;192(1):190-199. (PMID: 33152120)
Br J Haematol. 2014 Feb;164(4):546-54. (PMID: 24261566)
PLoS One. 2014 Jul 24;9(7):e103066. (PMID: 25058151)
Intern Med. 2019 Feb 1;58(3):355-360. (PMID: 30146592)
Bone Marrow Transplant. 2013 Feb;48(2):168-73. (PMID: 23208312)
Haematologica. 2014 Sep;99(9):e165-7. (PMID: 24907358)
J Obstet Gynaecol India. 2014 Dec;64(Suppl 1):26-8. (PMID: 25404800)
Haematologica. 2015 May;100(5):696-702. (PMID: 25616576)
Lancet Haematol. 2024 Mar;11(3):e206-e215. (PMID: 38335978)
Semin Hematol. 2016 Apr;53(2):115-9. (PMID: 27000736)
J Assoc Physicians India. 2015 Mar;63(3 Suppl):26-9. (PMID: 26529864)
Int J Gynaecol Obstet. 2006 Nov;95(2):115-20. (PMID: 16934813)
Obstet Gynecol. 1998 May;91(5 Pt 2):803-6. (PMID: 9572167)
Br J Haematol. 2012 Sep;158(5):563-8. (PMID: 22734439)
JAMA. 2010 Sep 22;304(12):1358-64. (PMID: 20858879)
Blood. 2008 Feb 1;111(3):1054-9. (PMID: 17989314)
Br J Haematol. 2024 Mar;204(3):784-804. (PMID: 38247114)
Blood. 2014 Mar 20;123(12):1818-25. (PMID: 24345753)
Rinsho Ketsueki. 1990 Feb;31(2):168-71. (PMID: 2329679)
J Obstet Gynaecol Res. 2003 Apr;29(2):67-72. (PMID: 12755524)
J Pediatr Hematol Oncol. 2011 Apr;33(3):172-8. (PMID: 21325968)
Pediatr Blood Cancer. 2017 Dec;64(12):. (PMID: 28708320)
Acta Obstet Gynecol Scand. 1999 May;78(5):458-61. (PMID: 10326895)
JAMA. 2003 Mar 5;289(9):1130-5. (PMID: 12622583)
Br J Haematol. 2012 May;157(3):339-46. (PMID: 22372373)
Haematologica. 2014 Oct;99(10):1574-81. (PMID: 25085353)
Blood. 1975 Mar;45(3):355-63. (PMID: 1090310)
Int J Hematol. 2016 Oct;104(4):454-61. (PMID: 27376944)
Br J Haematol. 2021 Jan;192(1):15-16. (PMID: 33152102)
Zhonghua Nei Ke Za Zhi. 2022 Apr 1;61(4):409-411. (PMID: 35340188)
Blood. 2011 Apr 28;117(17):4434-41. (PMID: 21233311)
Am J Hematol. 2014 Feb;89(2):125-9. (PMID: 24122901)
Blood. 2007 Aug 15;110(4):1397-400. (PMID: 17475907)
Bone Marrow Transplant. 2008 Jan;41(1):45-50. (PMID: 17982502)
Br J Haematol. 1988 Oct;70(2):177-82. (PMID: 3056497)
N Engl J Med. 2017 Apr 20;376(16):1540-1550. (PMID: 28423296)
Br J Haematol. 2026 Jan;208(1):295-303. (PMID: 40921497)
Chin Med Sci J. 1991 Dec;6(4):203-7. (PMID: 1813058)
Leuk Lymphoma. 2004 Mar;45(3):433-40. (PMID: 15160903)
Eur J Obstet Gynecol Reprod Biol. 2007 Apr;131(2):244-5. (PMID: 16787694)
N Engl J Med. 2018 Oct 25;379(17):1643-1656. (PMID: 30354958)
Br J Haematol. 1988 Jul;69(3):413-8. (PMID: 3044440)
Blood Adv. 2021 Jun 22;5(12):2660-2671. (PMID: 34156438)
Haematologica. 2017 Jul;102(7):1291-1298. (PMID: 28341733)
Br J Haematol. 2015 May;169(4):565-73. (PMID: 25683884)
Blood. 2011 Sep 1;118(9):2618-21. (PMID: 21677312)
Hematology Am Soc Hematol Educ Program. 2011;2011:84-9. (PMID: 22160017)
Pol Arch Intern Med. 2023 Aug 30;133(7-8):. (PMID: 36861425)
Bone Marrow Transplant. 2014 Jan;49(1):42-8. (PMID: 23912664)
Br J Haematol. 2025 Aug;207(2):582-590. (PMID: 40639944)
Blood Adv. 2025 Nov 25;9(22):5732-5735. (PMID: 40758947)
Br J Haematol. 2006 Jul;134(1):95-9. (PMID: 16803574)
Br J Haematol. 1989 Sep;73(1):121-6. (PMID: 2803967)
J Matern Fetal Neonatal Med. 2016;29(7):1120-4. (PMID: 26372009)
Hematology. 2020 Dec;25(1):48-54. (PMID: 31906834)
N Engl J Med. 2012 Jul 5;367(1):11-9. (PMID: 22762314)
Acta Haematol. 2019;142(3):162-170. (PMID: 31091521)
Int J Mol Sci. 2022 Oct 04;23(19):. (PMID: 36233062)
Blood. 2014 Oct 30;124(18):2775-83. (PMID: 25237198)
Haematologica. 2009 Dec;94(12):1661-8. (PMID: 19996117)
Br J Haematol. 2016 Jan;172(2):187-207. (PMID: 26568159)
Hematology. 2021 Dec;26(1):1025-1030. (PMID: 34895103)
Blood. 2016 Sep 1;128(9):1193-205. (PMID: 27281795)
Haematologica. 2016 May;101(5):644-52. (PMID: 26858357)
Cancer Genet. 2016 Jan-Feb;209(1-2):1-10. (PMID: 26702937)
Am J Med. 1979 Oct;67(4):564-71. (PMID: 495627)
Haematologica. 2022 Jan 01;107(1):126-133. (PMID: 33910334)
Leukemia. 2023 Dec;37(12):2479-2485. (PMID: 37794100)
Am J Clin Pathol. 2022 Nov 3;158(5):604-615. (PMID: 36018052)
N Engl J Med. 2015 Jul 2;373(1):35-47. (PMID: 26132940)
Semin Hematol. 2000 Jan;37(1):91-101. (PMID: 10676914)
Br J Haematol. 2008 Jan;140(2):197-205. (PMID: 18173756)
Ann Palliat Med. 2021 Jan;10(1):694-699. (PMID: 33353360)
Contributed Indexing: Keywords: Aplastic anemia; Asia Pacific; Delphi; Expert consensus; Recommendation
Entry Date(s): Date Created: 20260722 Date Completed: 20261005 Latest Revision: 20261015
Update Code: 20261016
PubMed Central ID: PMC13638747
DOI: 10.1007/s12185-026-04240-z
PMID: 42484952
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1865-3774
DOI:10.1007/s12185-026-04240-z